Home The Word Brain My Amedeo FAQ Privacy About   


Hanzi Hunter — ultra-fast Hanzi study

All 1,152 characters from the aioLingua manual

AbstractAboutThe 20 audio files

← aioLingua Chinese Online

← Chinese aioLingua PDF


  Nuclear Medicine

  Free Subscription


Articles published in Nuklearmedizin

Retrieve available abstracts of 72 articles:
HTML format



Single Articles


    October 2025
  1. VOLTIN CA, Kottlors J, Borchmann P, Godel P, et al
    Performance of a large language model in lymphoma stage assignment based on written PET/CT reports.
    Nuklearmedizin. 2025 Oct 14. doi: 10.1055/a-2707-4584.
    PubMed    


  2. KALANTARI F, Rendl G, Hecht S, Pirich C, et al
    Atypical local laryngeal cancer recurrence mimicking thyroid uptake on 18F-FDG PET/CT.
    Nuklearmedizin. 2025;64:316-317.
    PubMed    


  3. MANDIC A, Kraljevic I, Skoric Polovina T, Zibar Tomsic K, et al
    Diagnostic Performance of 99 mTc-Sestamibi SPECT/CT and 18F-Choline PET/CT in Locating Hyperfunctioning Parathyroid Glands in Patients with Primary Hyperparathyroidism.
    Nuklearmedizin. 2025;64:308-312.
    PubMed     Abstract available


  4. AMBULKAR KS, Shah R, Lila A, Sharma A, et al
    Outcomes of 68Ga-NODAGA-Exendin-4 PET/CT Guided Surgical Management of Insulinomas in MEN1: A Preliminary Study.
    Nuklearmedizin. 2025;64:301-307.
    PubMed     Abstract available


  5. MIKSCH J, Yousefzadeh-Nowshahr E, Hardiansyah D, Glatting G, et al
    First clinical application of silicon-based [(1)(8)F]siPSMA-14 in prostate cancer patients: A proof-of-concept study.
    Nuklearmedizin. 2025;64:285-293.
    PubMed     Abstract available


    September 2025
  6. CHIKASUE T, Kurata S, Edamitsu S, Koganemaru M, et al
    Central Conducting Lymphatic Abnormalities in Noonan Syndrome Identified Using SPECT/CT Lymphoscintigraphy.
    Nuklearmedizin. 2025 Sep 30. doi: 10.1055/a-2695-8007.
    PubMed    


    August 2025
  7. OKUDAN B, Atalay M, Hakkoymaz ZR, Seven B, et al
    Diagnostic value of presurgical 68Ga-PSMA-11 PET/CT in prostate cancer patients with different ISUP grade groups.
    Nuklearmedizin. 2025 Aug 22. doi: 10.1055/a-2665-8087.
    PubMed     Abstract available


  8. JOZANOVIC V, Lukic D, Brataljenovic M, Huic D, et al
    Diagnostic challenge in parathyroid imaging: incidental schwannoma mimicking primary hyperparathyroidism on 18F-fluorocholine PET/CT.
    Nuklearmedizin. 2025 Aug 22. doi: 10.1055/a-2655-5291.
    PubMed    


  9. TATOGLU MT, Alan Selcuk N, Erincik K
    Benign bone lesions mimicking metastasis on 68Ga-FAPI PET/CT.
    Nuklearmedizin. 2025;64:277-280.
    PubMed    


  10. GAMMEL MCM, Hansen K, Weber W, Rauscher I, et al
    From Metastases to Splenosis: Resolving SSR PET Pitfalls with Tc-99m-Labeled Denatured Red Blood Cell Scintigraphy.
    Nuklearmedizin. 2025;64:272-273.
    PubMed    


    June 2025
  11. LIU S, Pan Q, Xu H, Luo Y, et al
    Activation of fibroblast in intestinal Behcet's disease shown by 68Ga-FAPI-04 PET/CT.
    Nuklearmedizin. 2025;64:231-233.
    PubMed    


  12. YANG H, Zhang Y, Guan Z, Li C, et al
    The diagnostic performance of an [18F]FDG PET/CT algorithm for preoperative evaluation of extrahepatic cholangiocarcinoma: a retrospective study.
    Nuklearmedizin. 2025;64:205-214.
    PubMed     Abstract available


  13. DROPMANN JA, Kleespies A, Fuerst H, Kremer M, et al
    Importance of oxyphil cells for 99mTc-sestamibi uptake in primary hyperparathyroidism: a retrospective observational study.
    Nuklearmedizin. 2025;64:215-224.
    PubMed     Abstract available


    May 2025
  14. WENDLER T, Rogasch JMM, Bastian MB, Burchert W, et al
    Correction: Digitalization of Nuclear Medicine in Germany - Status Quo 2024.
    Nuklearmedizin. 2025 May 20. doi: 10.1055/a-2604-5823.
    PubMed    


  15. BAEHR M, Dietrich I, Liepe K
    [99mTc]Tc-PSMA SPECT/CT is a promising tool in the staging of renal cell carcinoma.
    Nuklearmedizin. 2025 May 12. doi: 10.1055/a-2578-7222.
    PubMed    


    April 2025
  16. BUCHERT R, Drzezga A, Schreckenberger M, Langen KJ, et al
    The Status of Neuroimaging with SPECT and PET in Germany: Results from the 1st Survey on Nuclear Neuroimaging in Germany in 2023.
    Nuklearmedizin. 2025 Apr 15. doi: 10.1055/a-2566-1487.
    PubMed     Abstract available


  17. LUNA R, Laheru DA, Shin EJ, Lossos C, et al
    Pancreatic Neuroendocrine Tumor incidentally found on 68Ga-PSMA PET/CT.
    Nuklearmedizin. 2025;64:177-179.
    PubMed    


  18. WENDLER T, Rogasch JMM, Bastian MB, Burchert W, et al
    Digitalization of Nuclear Medicine in Germany - Status Quo 2024.
    Nuklearmedizin. 2025;64:156-162.
    PubMed     Abstract available


  19. ORBOM A, Evans-Axelsson S, Jansson B, Vilhelmsson Timmermand O, et al
    Intratumoral distribution and pharmacokinetics of the radiolabeled ICAM-1 targeting monoclonal antibody R6.5 in a prostate cancer mouse model.
    Nuklearmedizin. 2025;64:163-169.
    PubMed     Abstract available


  20. EBRAHIMIFARD A, Rajabi H, Geramifar P, Luster M, et al
    The impact of the xSPECT reconstruction algorithms on the recovery coefficients value for small tumors: a phantom study with 177Lu.
    Nuklearmedizin. 2025;64:132-140.
    PubMed     Abstract available


  21. VOGT JK, Vogt WK, Heinzel A, Mottaghy FM, et al
    Comparison of 2D and 3D lung lobe quantification with Ventilation/Perfusion Ratio.
    Nuklearmedizin. 2025;64:142-149.
    PubMed     Abstract available


    March 2025
  22. BAUDE JK, Mottaghy FM, Derlin T, Fischer A, et al
    PSMA - Targeted Clinical Molecular Imaging of Atherosclerosis: Correlation with Cardiovascular Risk Factors.
    Nuklearmedizin. 2025;64:13-21.
    PubMed     Abstract available


    January 2025
  23. VURAL TOPUZ O, Bagbudar S, Aksu A, Soylemez Akkurt T, et al
    Radiomic signatures derived from baseline 18F FDG PET/CT imaging can predict tumor-infiltrating lymphocyte values in patients with primary breast cancer.
    Nuklearmedizin. 2025 Jan 28. doi: 10.1055/a-2512-8212.
    PubMed     Abstract available


    December 2024
  24. CEGLA P, Currie G, Wroblewska JP, Kazmierska J, et al
    [18F]FDG PET/CT Imaging and Hematological Parameters Can Help Predict HPV Status in Head and Neck Cancer.
    Nuklearmedizin. 2024 Dec 4. doi: 10.1055/a-2365-7808.
    PubMed     Abstract available


  25. GRUNERT M, Schenke SA, Konrad A, Schutze C, et al
    Thyroid scintigraphy: establishing a clinically useful normal range for 99mTc pertechnetate uptake.
    Nuklearmedizin. 2024;63:337-346.
    PubMed     Abstract available


    November 2024
  26. RUGGIERO C, Maracaja D, Rowe SP
    Langerhans Cell Histiocytosis-Associated Vertebra Plana on FDG PET.
    Nuklearmedizin. 2024 Nov 27. doi: 10.1055/a-2438-7469.
    PubMed    


  27. ZHAO G, Huang Z
    A Case of Thoracic SMARCA4-Deficient Undifferentiated Tumor on 18F-FDG PET/CT.
    Nuklearmedizin. 2024 Nov 20. doi: 10.1055/a-2383-2527.
    PubMed     Abstract available


  28. SCHULZ L, Funk GC, Kirchbacher K, Egger E, et al
    Comparison of whole-body 18F-FDG-PET/CT with 18F-FDG-PET/CT limited to skull base to upper abdomen for primary staging of lung cancer - a retrospective explorative analysis.
    Nuklearmedizin. 2024 Nov 11. doi: 10.1055/a-2438-7278.
    PubMed     Abstract available


    October 2024
  29. VOLTIN CA, Spreckelmeyer S, Essler M, Holzgreve A, et al
    Toward the future of nuclear medicine: How young professionals are getting involved and what plans they have.
    Nuklearmedizin. 2024;63:284-286.
    PubMed    


  30. VOGEL J, Haghghi S, Herkula C, Petersen M, et al
    Interobserver Agreement of visual and semi-quantitative methods in 99mTc-Methoxy-Isobuty-Isonitrile (MIBI) imaging for risk stratification of hypofunctional thyroid nodules.
    Nuklearmedizin. 2024;63:294-299.
    PubMed     Abstract available


  31. ZEIDLER R, Tiepolt S, Hesse S, Sabri O, et al
    Superimposing kidneys in [99mTc]MAG-3 and [99mTc]DMSA-scintigraphy in a tricky case of an extensive, displacing growing retroperitoneal liposarcoma.
    Nuklearmedizin. 2024;63:306-307.
    PubMed    


    September 2024
  32. JAFARI E, Manafi-Farid R, Ahmadzadehfar H, Salek F, et al
    Prognostic Significance of Baseline Clinical and [68Ga]Ga-PSMA PET Derived Parameters on Biochemical Response, Overall Survival, and PSA Progression-Free Survival in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Undergoing [177Lu]Lu
    Nuklearmedizin. 2024 Sep 3. doi: 10.1055/a-2365-8113.
    PubMed     Abstract available


    August 2024
  33. RAHBAR NIKOUKAR L, Seifert R, Ventura D, Schindler P, et al
    Prognostic value of pretherapeutic 68Ga-PSMA-11-PET based imaging parameters in mCRPC patients treated with PSMA radioligands.
    Nuklearmedizin. 2024 Aug 29. doi: 10.1055/a-2383-2468.
    PubMed     Abstract available


  34. VOGT JK, Vogt WK, Heinzel A, Mottaghy FM, et al
    Computational Decision Support for PE Diagnosis based on Ventilation Perfusion Ratio.
    Nuklearmedizin. 2024;63:259-266.
    PubMed     Abstract available


    July 2024
  35. LANDAU F, Hermann S, Schelhaas S, Schafers M, et al
    18F-labelled gentiobiose as potential PET-radiotracer for specific bacterial imaging: precursor synthesis, radiolabelling and in vitro evaluation.
    Nuklearmedizin. 2024 Jul 31. doi: 10.1055/a-2365-8054.
    PubMed     Abstract available


  36. BREDENSTEINER L, Ventura D, Rassek P, Schafers M, et al
    Determination of the optimal imaging protocol for [18F]PSMA-PET-CT for the detection of bone metastases in prostate cancer patients.
    Nuklearmedizin. 2024 Jul 12. doi: 10.1055/a-2344-6825.
    PubMed     Abstract available


    May 2024
  37. SCHMIDT M, Hohberg M, Felcht M, Kuhn T, et al
    [Nuclear medicine procedure guideline for sentinel lymph node localization].
    Nuklearmedizin. 2024 May 24. doi: 10.1055/a-2319-8306.
    PubMed     Abstract available


  38. HEIDEMANNS S, Trautmann S, Weidt D, Hellwig D, et al
    Update of the competence-based catalog of learning objectives in nuclear medicine for the study of human medicine in Germany.
    Nuklearmedizin. 2024 May 22. doi: 10.1055/a-2319-7549.
    PubMed     Abstract available


    April 2024
  39. WIELENBERG CF, Fostitsch JC, Volz C, Marks R, et al
    FDG-PET/CT is a powerful tool to predict and evaluate response to chimeric antigen receptor (CAR) T-cell therapy in Non-Hodgkin-Lymphoma (NHL).
    Nuklearmedizin. 2024 Apr 9. doi: 10.1055/a-2283-8417.
    PubMed     Abstract available


  40. BOCK F, Frerker B, Schubert L, Rennau H, et al
    Impact of 68Ga-PSMA PET/CT on radiation treatment planning of prostate cancer patients.
    Nuklearmedizin. 2024 Apr 5. doi: 10.1055/a-2284-0593.
    PubMed     Abstract available


  41. SAEED S, Dimopoulos I, Begum N, Kroger JR, et al
    [Not Available].
    Nuklearmedizin. 2024;63:78-80.
    PubMed    


  42. WERNER R, Haug A, Buske C, Heidegger S, et al
    CXCR4-targeted Theranostics in Hematooncology: Opportunities and Challenges.
    Nuklearmedizin. 2024;63:57-61.
    PubMed     Abstract available


    March 2024
  43. GACULA SIG, Kunte SC, Unterrainer LM, Rubenthaler J, et al
    Correction: Divergent growth on [18F]FDG PET/CT in a case of co-existing pulmonary metastatic leiomyosarcoma and papillary thyroid carcinoma.
    Nuklearmedizin. 2024 Mar 25. doi: 10.1055/a-2286-9571.
    PubMed    


  44. USLU H, Sahin D, Tatoglu MT, Ibisoglu E, et al
    Growing Teratoma Syndrome Revealed By F-18 FDG PET/CT.
    Nuklearmedizin. 2024 Mar 14. doi: 10.1055/a-2273-2350.
    PubMed    


  45. GACULA SIG, Kunte SC, Unterrainer LM, Rubenthaler J, et al
    Divergent growth on [18F]FDG PET/CT in a case of co-existing pulmonary metastatic leiomyosarcoma and papillary thyroid carcinoma.
    Nuklearmedizin. 2024 Mar 11. doi: 10.1055/a-2273-2447.
    PubMed    


  46. LIU Y, Tang W, Huang Z
    Correction: 99mTc-MDP Bone Scan and 18F-FDG PET/CT Imaging of Primary Hepatic Osteosarcoma.
    Nuklearmedizin. 2024 Mar 4. doi: 10.1055/a-2275-1035.
    PubMed    


    February 2024
  47. CHEN M, Liu Y
    Correction: 18F-FDG PET/CT images of adult pulmonary blastoma: a case report.
    Nuklearmedizin. 2024 Feb 20. doi: 10.1055/a-2265-4049.
    PubMed    


  48. AYDAR S, Knobl H, Burchert W, Lindner O, et al
    Diagnostic accuracy of artificial intelligence-enabled vectorcardiography versus myocardial perfusion SPECT in patients with suspected or known coronary heart disease.
    Nuklearmedizin. 2024 Feb 20. doi: 10.1055/a-2263-2322.
    PubMed     Abstract available


  49. CHEN M, Liu Y
    18F-FDG PET/CT images of adult pulmonary blastoma: a case report.
    Nuklearmedizin. 2024 Feb 7. doi: 10.1055/a-2237-8775.
    PubMed    


  50. UMUTLU L, Nensa F, Demircioglu A, Antoch G, et al
    Radiomics Analysis of Multiparametric PET/MRI for N- and M-Staging in Patients with Primary Cervical Cancer.
    Nuklearmedizin. 2024;63:34-42.
    PubMed     Abstract available


  51. FISCHER M, Schneider-Eicke J
    Nonosseous bone seeking tracer focal uptake in the conventional scintigraphy.
    Nuklearmedizin. 2024;63:45-47.
    PubMed    


  52. DIETLEIN M, Grunwald F, Schmidt M, Kreissl MC, et al
    [Guideline for Radioiodine Therapy for Benign Thyroid Diseases (6/2022 - AWMF No. 031-003)].
    Nuklearmedizin. 2024;63:8-20.
    PubMed     Abstract available


    January 2024
  53. FREUDENBERG R, Kastner D, Kotzerke J, Brogsitter C, et al
    [Evaluation of risk analysis in treatment with unsealed radioactive substances in nuclear medicine].
    Nuklearmedizin. 2024 Jan 23. doi: 10.1055/a-2237-8639.
    PubMed    


  54. MAMAN A
    Incidental Papillary Thyroid Carcinoma Detected by Ga-68 DOTATATE PET/CT: A Rare Case Study and Clinical Considerations.
    Nuklearmedizin. 2024 Jan 23. doi: 10.1055/a-2238-4186.
    PubMed    


  55. NOURBAKHSH S, Salehi Y, Farzanehfar S, Ghaletaki R, et al
    FAPI PET/CT provides higher uptake and better target to back ground in recurrent and metastatic tumors of patients with Iodine refractory papillary thyroid cancer compared with FDG PET CT.
    Nuklearmedizin. 2024 Jan 8. doi: 10.1055/a-2185-7746.
    PubMed     Abstract available


  56. ARSLANTAS E, Aycicek A, Esen Akkas B, Tahtakesen Gucer TN, et al
    The Role of FDG- PET/CT in Detecting Bone Marrow Involvement in Childhood Solid Tumors.
    Nuklearmedizin. 2024 Jan 8. doi: 10.1055/a-2224-9441.
    PubMed     Abstract available


  57. VURAL TOPUZ O, Bagbudar S
    Cervical Cancer Metastasis to the Stomach Masquerading as Primary Gastric Cancer: A Case Report of a Rare Metastasis Detected via 18F-FDG PET/CT.
    Nuklearmedizin. 2024 Jan 8. doi: 10.1055/a-2224-9673.
    PubMed    


  58. SANTO G, Di Santo G, Zelger B, Virgolini I, et al
    Incidental Finding of a Pancreatic Adenocarcinoma on [68Ga]Ga-PSMA-11 PET/CT in a mCRPC patient under [177Lu]Lu-PSMA-617 Radioligand Therapy.
    Nuklearmedizin. 2024 Jan 8. doi: 10.1055/a-2221-3220.
    PubMed    


    December 2023
  59. SERFLING SE, Buck A, Rowe SP, Higuchi T, et al
    Red Bull PET/CT.
    Nuklearmedizin. 2023 Dec 22. doi: 10.1055/a-2195-0138.
    PubMed     Abstract available


  60. ROGASCH JMM, Shi K, Kersting D, Seifert R, et al
    Methodological evaluation of original articles on radiomics and machine learning for outcome prediction based on positron emission tomography (PET).
    Nuklearmedizin. 2023;62:361-369.
    PubMed     Abstract available


  61. WENDLER T, Kreissl MC, Schemmer B, Rogasch JMM, et al
    Artificial Intelligence-powered automatic volume calculation in medical images - available tools, performance and challenges for nuclear medicine.
    Nuklearmedizin. 2023;62:343-353.
    PubMed     Abstract available


  62. HELLWIG D, Hellwig NC, Boehner S, Fuchs T, et al
    Artificial Intelligence and Deep Learning for Advancing PET Image Reconstruction: State-of-the-Art and Future Directions.
    Nuklearmedizin. 2023;62:334-342.
    PubMed     Abstract available


  63. MIEDERER I, Rogasch JMM, Wendler T
    AI in Nuclear Medicine - a review of the current situation.
    Nuklearmedizin. 2023;62:332-333.
    PubMed    


    November 2023
  64. LOHMANN P, Bundschuh RA, Miederer I, Mottaghy FM, et al
    Clinical Applications of Radiomics in Nuclear Medicine.
    Nuklearmedizin. 2023 Nov 7. doi: 10.1055/a-2191-3271.
    PubMed     Abstract available


    October 2023
  65. FUCHS T, Kaiser L, Muller D, Papp L, et al
    Enhancing Interoperability and Harmonisation of Nuclear Medicine Image Data and Associated Clinical Data.
    Nuklearmedizin. 2023 Oct 31. doi: 10.1055/a-2187-5701.
    PubMed     Abstract available


  66. RASSEK P, Bobe S, Kies P, Roll W, et al
    The value of core needle biopsy in the diagnostic workup of a [18F]FDG-PET positive thyroid metastasis from colorectal cancer.
    Nuklearmedizin. 2023 Oct 23. doi: 10.1055/a-2178-6908.
    PubMed    


  67. BROSCH-LENZ JF, Delker A, Schmidt F, Tran-Gia J, et al
    On the Use of Artificial Intelligence for Dosimetry of Radiopharmaceutical Therapies.
    Nuklearmedizin. 2023 Oct 12. doi: 10.1055/a-2179-6872.
    PubMed     Abstract available


  68. MOON H, Ku EJ, Kim C
    Ectopic Thyroid Tissue in the Uterus Identified by Iodine-131 SPECT/CT.
    Nuklearmedizin. 2023;62:294-295.
    PubMed    


  69. KUSTNER T, Hepp T, Seith F
    Multiparametric Oncologic Hybrid Imaging: Machine Learning Challenges and Opportunities.
    Nuklearmedizin. 2023;62:306-313.
    PubMed     Abstract available


    September 2023
  70. DEININGER K, Raacke JN, Yousefzadeh-Nowshahr E, Kropf-Sanchen C, et al
    Combined morphologic-metabolic biomarkers from [18F]FDG-PET/CT stratify prognostic groups in low-risk NSCLC.
    Nuklearmedizin. 2023 Sep 11. doi: 10.1055/a-2150-4130.
    PubMed     Abstract available


  71. MIEDERER I, Rogasch JMM, Fischer R, Fuchs T, et al
    The Medical Informatics Initiative and the Network University Medicine - Perspectives for Nuclear Medicine.
    Nuklearmedizin. 2023 Sep 8. doi: 10.1055/a-2067-7642.
    PubMed     Abstract available


    August 2023
  72. FROHLICH M, Schmalzing M, Buck A, Bley TA, et al
    PET-Derived Increased Inflammation in Large Vessels is linked to Relapse-Free Survival in Patients with Giant Cell Arteritis.
    Nuklearmedizin. 2023;62:229-234.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Nuclear Medicine is free of charge.